Statement of Changes in Beneficial Ownership (4)
September 28 2021 - 07:47PM
Edgar (US Regulatory)
FORM 4
[X]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Frazier Life Sciences Public Fund, L.P. |
2. Issuer Name and Ticker or Trading Symbol
Viridian Therapeutics, Inc.DE
[
VRDN
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Last)
(First)
(Middle)
C/O FRAZIER HEALTHCARE PARTNERS, 601 UNION STREET, SUITE 3200 |
3. Date of Earliest Transaction
(MM/DD/YYYY)
9/23/2021 |
(Street)
SEATTLE, WA 98101
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
___ Form filed by One Reporting Person
_
X
_ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 9/23/2021 | | P | | 200000 | A | $11.00 | 1505200 (1) | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | These shares are held directly by Frazier Life Sciences Public Fund L.P. The general partner of Frazier Life Sciences Public Fund L.P. is FHMLSP, L.P. and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Frazier Life Sciences Public Fund L.P. FHMLSP, L.P. and FHMLSP, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by Frazier Life Sciences Public Fund L.P., except to the extent of its pecuniary interest therein, if any. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Frazier Life Sciences Public Fund, L.P. C/O FRAZIER HEALTHCARE PARTNERS 601 UNION STREET, SUITE 3200 SEATTLE, WA 98101 |
| X |
|
|
FHMLSP, L.P. C/O FRAZIER HEALTHCARE PARTNERS 601 UNION STREET, SUITE 3200 SEATTLE, WA 98101 |
| X |
|
|
FHMLSP, L.L.C. C/O FRAZIER HEALTHCARE PARTNERS 601 UNION STREET, SUITE 3200 SEATTLE, WA 98101 |
| X |
|
|
Signatures
|
Frazier Life Sciences Public Fund L.P., By: FHMLSP, L.P., its General Partner. By: FHMLSP, L.L.C., its General Partner, By: /s/ Steve R. Bailey, Chief Financial Officer | | 9/28/2021 |
**Signature of Reporting Person | Date |
FHMLSP, L.P., By: FHMLSP, L.L.C., its General Partner, By: /s/ Steve R. Bailey, Chief Financial Officer | | 9/28/2021 |
**Signature of Reporting Person | Date |
FHMLSP, L.L.C., By: /s/ Steve R. Bailey, Chief Financial Officer | | 9/28/2021 |
**Signature of Reporting Person | Date |
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Viridian Therapeutics (NASDAQ:VRDN)
Historical Stock Chart
From Mar 2023 to Mar 2024